Patient Preferences for First-Line Treatment of Locally Advanced or Metastatic Urothelial Carcinoma: An Application of Multidimensional Thresholding

Apolo et al. (Wed,) studied this question.

www.synapsesocial.com/papers/68e5a818b6db6435875427d1 — DOI: https://doi.org/10.1007/s40271-024-00709-3

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Carboplatin and cisplatin hypersensitivity - pattern, potential mechanism, and desensitization· 2004 · 3 citations
2. Medical oncologists’ first-line treatment preferences in metastatic urothelial carcinoma.· 2020 · 2 citations
3. Patient Preferences in the Medical Product Lifecycle· 2019 · 17 citations
4. Randomized phase III trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as perioperative chemotherapy for muscle invasive urothelial bladder cancer (MIUBC): Preliminary results of the GETUG/AFU V05 VESPER trial on toxicity and pathological responses.· 2020 · 16 citations
5. Current Practices for Accounting for Preference Heterogeneity in Health-Related Discrete Choice Experiments: A Systematic Review· 2022 · 20 citations